Literature DB >> 19855289

The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension.

Richard A Lewis1, Ronald L Gross, Kenneth N Sall, Rhett M Schiffman, Ching Chi Liu, Amy L Batoosingh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19855289     DOI： 10.1097/IJG.0b013e3181bdb586

Source DB:  PubMed          Journal:  J Glaucoma        ISSN： 1057-0829            Impact factor:   2.503


× No keyword cloud information.
  15 in total

1.  Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy.

Authors:  Ai-Wei Liu; Lin-Yang Gan; Xiang Yao; Jian Zhou
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

2.  Bimatoprost/timolol fixed combination (BTFC) in patients with primary open angle glaucoma or ocular hypertension in Greece.

Authors:  Tryfon G Rotsos; Vasso G Kliafa; Kevin J Asher; Dimitrios Papaconstantinou
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779

3.  Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials.

Authors:  David Wirta; Amanda M Vandenburgh; Emily Weng; Scott M Whitcup; Sef Kurstjens; Frederick C Beddingfield
Journal:  Clin Ophthalmol       Date:  2011-06-07

4.  Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients.

Authors:  M Francesca Cordeiro; Ivan Goldberg; Rhett Schiffman; Paula Bernstein; Marina Bejanian
Journal:  Clin Ophthalmol       Date:  2015-08-31

5.  Diurnal intraocular pressure with bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in healthy subjects.

Authors:  Seong Hee Shim; Joon Mo Kim; Chul Young Choi; Chan Yun Kim
Journal:  Korean J Ophthalmol       Date:  2014-01-21

Review 6.  Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products.

Authors:  Gábor Holló; Jouni Vuorinen; Juhani Tuominen; Teppo Huttunen; Auli Ropo; Norbert Pfeiffer
Journal:  Adv Ther       Date:  2014-09-12       Impact factor: 3.845

Review 7.  The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies.

Authors:  Nathan M Radcliffe
Journal:  Clin Ophthalmol       Date:  2014-12-12

8.  Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.

Authors:  Alfonso García-López; José A Paczka; Jesús Jiménez-Román; Curt Hartleben
Journal:  BMC Ophthalmol       Date:  2014-12-19       Impact factor: 2.209

9.  Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.

Authors:  Ivan Goldberg; Rafael Gil Pina; Aitor Lanzagorta-Aresti; Rhett M Schiffman; Charlie Liu; Marina Bejanian
Journal:  Br J Ophthalmol       Date:  2014-03-25       Impact factor: 4.638

10.  Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenon.

Authors:  Jie Shen; Marina Bejanian
Journal:  Clin Ophthalmol       Date:  2016-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.